Friday, December 6, 2013
GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
Thursday, November 21, 2013
Theravance to Present at the 25th Annual Piper Jaffray Healthcare Conference
Monday, November 18, 2013
RELVAR« ELLIPTA« Receives European Marketing Authorisation for the Treatment of Asthma and COPD
Medicines that make a difference┬«
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
We partner with pharmaceutical companies to accelerate development and commercialization of our product candidates.
Every day at Theravance, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance discovers, develops and brings important medicines to patients by: